Data were presented by Dr. Kim Nguyen Chi, Principal Investigator and a medical oncologist at BC Cancer Agency - Vancouver Centre, representing the NCIC - Clinical Trials Group (NCIC-CTG). The survival curves presented by Dr. Chi are available at www.oncogenex.com.
"A 6.9 month median overall survival difference would represent a significant improvement over the current standard docetaxel therapy," said Dr. Chi, Principal Investigator of the NCIC-CTG sponsored trial and presenter of the data at ASCO. "Docetaxel was approved in 2004 based on a 2.4 month survival advantage in advanced prostate cancer. The consistent results in favor of the OGX-011 treatment arm in this trial are a clear indication that Phase 3 trials are warranted."
"A 39% reduction in death, consistent with the previously disclosed preliminary analysis, would be a significant advancement for treatment in this patient population," said Scott Cormack, president and CEO of OncoGenex. "The multivariate analysis shows an even greater reduction in death rate than our preliminary data and increases our confidence that we are seeing a real and meaningful survival benefit for patients treated with OGX-011 in this Phase 2 study."
About the Randomized Phase 2 Trial and the Trial Results
The trial enrolled 82 patients at 12 sites in Canada and the U.S. from September 2005 to December 2006. Patients were randomized to one of two treatment arms to receive either 640 mg per week of OGX-011 by intravenous infusion in combination with docetaxel and prednisone or docetaxel and prednisone alone. Patients in both treatment arms receive therapy until disease progression, toxicity or after receiving ten 3-week cycles of therapy. The primary endpoint of the trial was to achieve a 50% reduction in PSA from baseline in over 50% of the patients treated w
|SOURCE OncoGenex Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved